Literature DB >> 13932966

The use of hyperimmune antivaccinia gamma-globulin for the prevention and treatment of smallpox.

S S MARENNIKOVA.   

Abstract

Smallpox prophylaxis studies having shown that the classical Jennerian type of vaccination may in some instances prove inadequate to prevent the development of the disease or may be contra-indicated for certain persons, attempts were made to evolve a method which could supplement or replace such vaccination. Investigations reported in this paper have demonstrated that the administration of gamma-globulin obtained from the sera of various animals hyperimmunized with vaccinia virus gives highly effective results in the prevention of different forms of experimental vaccinial infection. Encouraging results were also obtained with this gamma-globulin given prophylactically to 13 persons who had been in close contact with smallpox patients during an outbreak of this disease in Moscow in 1960. The author suggests that hyperimmune antivaccinia gamma-globulin of animal origin may also prove effective in the treatment of postvaccinal complications.

Entities:  

Keywords:  GAMMA GLOBULIN; SMALLPOX; VACCINIA VIRUS

Mesh:

Substances:

Year:  1962        PMID: 13932966      PMCID: PMC2555760     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  4 in total

1.  Anti-vaccinial gamma-globulin in smallpox prophylaxis.

Authors:  E R PEIRCE; F S MELVILLE; A W DOWNIE; M J DUCKWORTH
Journal:  Lancet       Date:  1958-09-20       Impact factor: 79.321

2.  [Experimental preparation and studies on anti-smallpox gamma globulin].

Authors:  S S MARENNIKOVA; N A PONOMAREVA; Z I OGORODNIKOVA; M N DURASOVA
Journal:  Vopr Virusol       Date:  1958 Nov-Dec

3.  Hyperimmune vaccinal gamma globulin; source, evaluation, and use in prophylaxis and therapy.

Authors:  C H KEMPE; T O BERGE; B ENGLAND
Journal:  Pediatrics       Date:  1956-08       Impact factor: 7.124

4.  [Smallpox in metropolitan areas; recent studies on its epidemiology].

Authors:  R CROSNIER
Journal:  Sem Hop       Date:  1956-06-22
  4 in total
  10 in total

1.  Antiviral immunity following smallpox virus infection: a case-control study.

Authors:  Erika Hammarlund; Matthew W Lewis; Jon M Hanifin; Motomi Mori; Caroline W Koudelka; Mark K Slifka
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  TETRACYCLINES IN THE DOCK.

Authors:  K C CHAUDHURI
Journal:  Indian J Pediatr       Date:  1964-01       Impact factor: 1.967

3.  Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.

Authors:  Megan M McCausland; Mohammed Rafii-El-Idrissi Benhnia; Lindsay Crickard; John Laudenslager; Steven W Granger; Tomoyuki Tahara; Ralph Kubo; Lilia Koriazova; Shinichiro Kato; Shane Crotty
Journal:  Antivir Ther       Date:  2010

4.  Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine.

Authors:  Mohammed Rafii-El-Idrissi Benhnia; Megan M McCausland; Hua-Poo Su; Kavita Singh; Julia Hoffmann; D Huw Davies; Philip L Felgner; Steven Head; Alessandro Sette; David N Garboczi; Shane Crotty
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

5.  The smallpox vaccine induces an early neutralizing IgM response.

Authors:  Juan E Moyron-Quiroz; Megan M McCausland; Robin Kageyama; Alessandro Sette; Shane Crotty
Journal:  Vaccine       Date:  2009-10-12       Impact factor: 3.641

Review 6.  Wanted, dead or alive: new viral vaccines.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Antiviral Res       Date:  2009-09-04       Impact factor: 5.970

7.  Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement.

Authors:  Mohammed Rafii-El-Idrissi Benhnia; Megan M McCausland; Juan Moyron; John Laudenslager; Steven Granger; Sandra Rickert; Lilia Koriazova; Ralph Kubo; Shinichiro Kato; Shane Crotty
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

8.  Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5.

Authors:  Mohammed Rafii-El-Idrissi Benhnia; Megan M McCausland; John Laudenslager; Steven W Granger; Sandra Rickert; Lilia Koriazova; Tomoyuki Tahara; Ralph T Kubo; Shinichiro Kato; Shane Crotty
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

9.  Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections.

Authors:  Yuhong Xiao; Stuart N Isaacs
Journal:  Viruses       Date:  2010-10       Impact factor: 5.048

10.  Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies.

Authors:  Lindsay Crickard; Tahar Babas; Sidharth Seth; Peter Silvera; Lilia Koriazova; Shane Crotty
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.